Virtual Clinical Trials Comprehensive Study by Application (Oncology, Cardiovascular Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Others), Design (Interventional, Observational, Expanded Access) Players and Region - Global Market Outlook to 2027

Virtual Clinical Trials Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Virtual Clinical Trials?
A virtual clinical trial also known as remote or decentralized clinical trials it refers to clinical trial processes that are enabled by digital technology. Because this is a relatively new model of clinical trials in terms of adoption, it is a means of conducting clinical research that is underutilized. Virtual clinical trials, on the other hand, have the potential to induce significant digital changes in clinical research methodology, resulting in a more patient-centric ecosystem. These solutions take into account a wide range of technological advantages, including innovative applications, electronic devices, online social engagement platforms, artificial intelligence, robotic process automation, and machine learning, to name a few. Virtual clinical trials, without a doubt, take advantage of the potential of telehealth/digital technology by incorporating virtual patient monitoring, wearable medical devices, remote SDV, and other features to perform safer and more effective clinical trial research. These virtual trials are patient-centered, low-cost, and simple to run.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledICON, plc (Ireland), Parexel International Corporation (United States), IQVIA (United States), Covance (United States), PRA Health Sciences (United States), LEO Innovation Lab (Denmark), Medidata Solutions (United States), Oracle (United States), CRF Health (United States), Clinical Ink Inc. (United States) and Medable, Inc. (United States)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Virtual Clinical Trials market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

ICON, plc (Ireland), Parexel International Corporation (United States), IQVIA (United States), Covance (United States), PRA Health Sciences (United States), LEO Innovation Lab (Denmark), Medidata Solutions (United States), Oracle (United States), CRF Health (United States), Clinical Ink Inc. (United States) and Medable, Inc. (United States) are some of the key players that are part of study coverage.

The market study is broken down, by Application (Oncology, Cardiovascular Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology and Others) and major geographies with country level break-up.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Virtual Clinical Trials market by Type, Application and Region.

On the basis of geography, the market of Virtual Clinical Trials has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Design, the sub-segment i.e. Interventional will boost the Virtual Clinical Trials market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In March 2020 -Medable has developed a new TeleVisit mobile application that can be used by patients worldwide to connect virtually with their clinical trial sites. The application makes it possible for clinical trial research to progress in an environment where many patients are being told to stay home and avoid social interaction.


Market Trend
  • Rising research and development to deliver advanced healthcare infrastructure
  • The high adoption of VCTs for dermatological testing

Market Drivers
  • Increasing prevalence of diseases and high demand for clinical trials
  • Rapid digitization of the healthcare infrastructure

Opportunities
  • Increasing per capita income and government actions that are beneficial
  • Demand for virtual and remote testing solutions to capture data safely and efficiently is increasing

Restraints
  • High cost of installations

Challenges
  • Some patients may not be comfortable wearing wearables or utilizing other gadgets all day in the case of continuous monitoring


Key Target Audience
Virtual Clinical Trials Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Oncology
  • Cardiovascular Autoimmune/Inflammation
  • Cardiovascular Disease
  • Metabolic/Endocrinology
  • Others
By Design
  • Interventional
  • Observational
  • Expanded Access

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of diseases and high demand for clinical trials
      • 3.2.2. Rapid digitization of the healthcare infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Some patients may not be comfortable wearing wearables or utilizing other gadgets all day in the case of continuous monitoring
    • 3.4. Market Trends
      • 3.4.1. Rising research and development to deliver advanced healthcare infrastructure
      • 3.4.2. The high adoption of VCTs for dermatological testing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Virtual Clinical Trials, by Application, Design and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Virtual Clinical Trials (Value)
      • 5.2.1. Global Virtual Clinical Trials by: Application (Value)
        • 5.2.1.1. Oncology
        • 5.2.1.2. Cardiovascular Autoimmune/Inflammation
        • 5.2.1.3. Cardiovascular Disease
        • 5.2.1.4. Metabolic/Endocrinology
        • 5.2.1.5. Others
      • 5.2.2. Global Virtual Clinical Trials by: Design (Value)
        • 5.2.2.1. Interventional
        • 5.2.2.2. Observational
        • 5.2.2.3. Expanded Access
      • 5.2.3. Global Virtual Clinical Trials Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Virtual Clinical Trials (Price)
  • 6. Virtual Clinical Trials: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ICON, plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Parexel International Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. IQVIA (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Covance (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. PRA Health Sciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LEO Innovation Lab (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medidata Solutions (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oracle (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CRF Health (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Clinical Ink Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Medable, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Virtual Clinical Trials Sale, by Application, Design and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Virtual Clinical Trials (Value)
      • 7.2.1. Global Virtual Clinical Trials by: Application (Value)
        • 7.2.1.1. Oncology
        • 7.2.1.2. Cardiovascular Autoimmune/Inflammation
        • 7.2.1.3. Cardiovascular Disease
        • 7.2.1.4. Metabolic/Endocrinology
        • 7.2.1.5. Others
      • 7.2.2. Global Virtual Clinical Trials by: Design (Value)
        • 7.2.2.1. Interventional
        • 7.2.2.2. Observational
        • 7.2.2.3. Expanded Access
      • 7.2.3. Global Virtual Clinical Trials Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Virtual Clinical Trials (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Virtual Clinical Trials: by Application(USD Million)
  • Table 2. Virtual Clinical Trials Oncology , by Region USD Million (2016-2021)
  • Table 3. Virtual Clinical Trials Cardiovascular Autoimmune/Inflammation , by Region USD Million (2016-2021)
  • Table 4. Virtual Clinical Trials Cardiovascular Disease , by Region USD Million (2016-2021)
  • Table 5. Virtual Clinical Trials Metabolic/Endocrinology , by Region USD Million (2016-2021)
  • Table 6. Virtual Clinical Trials Others , by Region USD Million (2016-2021)
  • Table 7. Virtual Clinical Trials: by Design(USD Million)
  • Table 8. Virtual Clinical Trials Interventional , by Region USD Million (2016-2021)
  • Table 9. Virtual Clinical Trials Observational , by Region USD Million (2016-2021)
  • Table 10. Virtual Clinical Trials Expanded Access , by Region USD Million (2016-2021)
  • Table 11. South America Virtual Clinical Trials, by Country USD Million (2016-2021)
  • Table 12. South America Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 13. South America Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 14. Brazil Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 15. Brazil Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 16. Argentina Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 17. Argentina Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 18. Rest of South America Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 19. Rest of South America Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 20. Asia Pacific Virtual Clinical Trials, by Country USD Million (2016-2021)
  • Table 21. Asia Pacific Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 22. Asia Pacific Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 23. China Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 24. China Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 25. Japan Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 26. Japan Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 27. India Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 28. India Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 29. South Korea Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 30. South Korea Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 31. Taiwan Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 32. Taiwan Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 33. Australia Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 34. Australia Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 35. Rest of Asia-Pacific Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 36. Rest of Asia-Pacific Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 37. Europe Virtual Clinical Trials, by Country USD Million (2016-2021)
  • Table 38. Europe Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 39. Europe Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 40. Germany Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 41. Germany Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 42. France Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 43. France Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 44. Italy Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 45. Italy Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 46. United Kingdom Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 47. United Kingdom Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 48. Netherlands Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 49. Netherlands Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 50. Rest of Europe Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 51. Rest of Europe Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 52. MEA Virtual Clinical Trials, by Country USD Million (2016-2021)
  • Table 53. MEA Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 54. MEA Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 55. Middle East Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 56. Middle East Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 57. Africa Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 58. Africa Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 59. North America Virtual Clinical Trials, by Country USD Million (2016-2021)
  • Table 60. North America Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 61. North America Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 62. United States Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 63. United States Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 64. Canada Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 65. Canada Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 66. Mexico Virtual Clinical Trials, by Application USD Million (2016-2021)
  • Table 67. Mexico Virtual Clinical Trials, by Design USD Million (2016-2021)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Virtual Clinical Trials: by Application(USD Million)
  • Table 80. Virtual Clinical Trials Oncology , by Region USD Million (2022-2027)
  • Table 81. Virtual Clinical Trials Cardiovascular Autoimmune/Inflammation , by Region USD Million (2022-2027)
  • Table 82. Virtual Clinical Trials Cardiovascular Disease , by Region USD Million (2022-2027)
  • Table 83. Virtual Clinical Trials Metabolic/Endocrinology , by Region USD Million (2022-2027)
  • Table 84. Virtual Clinical Trials Others , by Region USD Million (2022-2027)
  • Table 85. Virtual Clinical Trials: by Design(USD Million)
  • Table 86. Virtual Clinical Trials Interventional , by Region USD Million (2022-2027)
  • Table 87. Virtual Clinical Trials Observational , by Region USD Million (2022-2027)
  • Table 88. Virtual Clinical Trials Expanded Access , by Region USD Million (2022-2027)
  • Table 89. South America Virtual Clinical Trials, by Country USD Million (2022-2027)
  • Table 90. South America Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 91. South America Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 92. Brazil Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 93. Brazil Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 94. Argentina Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 95. Argentina Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 96. Rest of South America Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 97. Rest of South America Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 98. Asia Pacific Virtual Clinical Trials, by Country USD Million (2022-2027)
  • Table 99. Asia Pacific Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 100. Asia Pacific Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 101. China Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 102. China Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 103. Japan Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 104. Japan Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 105. India Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 106. India Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 107. South Korea Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 108. South Korea Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 109. Taiwan Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 110. Taiwan Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 111. Australia Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 112. Australia Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 113. Rest of Asia-Pacific Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 114. Rest of Asia-Pacific Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 115. Europe Virtual Clinical Trials, by Country USD Million (2022-2027)
  • Table 116. Europe Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 117. Europe Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 118. Germany Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 119. Germany Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 120. France Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 121. France Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 122. Italy Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 123. Italy Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 124. United Kingdom Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 125. United Kingdom Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 126. Netherlands Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 127. Netherlands Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 128. Rest of Europe Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 129. Rest of Europe Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 130. MEA Virtual Clinical Trials, by Country USD Million (2022-2027)
  • Table 131. MEA Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 132. MEA Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 133. Middle East Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 134. Middle East Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 135. Africa Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 136. Africa Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 137. North America Virtual Clinical Trials, by Country USD Million (2022-2027)
  • Table 138. North America Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 139. North America Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 140. United States Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 141. United States Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 142. Canada Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 143. Canada Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 144. Mexico Virtual Clinical Trials, by Application USD Million (2022-2027)
  • Table 145. Mexico Virtual Clinical Trials, by Design USD Million (2022-2027)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Virtual Clinical Trials: by Application USD Million (2016-2021)
  • Figure 5. Global Virtual Clinical Trials: by Design USD Million (2016-2021)
  • Figure 6. South America Virtual Clinical Trials Share (%), by Country
  • Figure 7. Asia Pacific Virtual Clinical Trials Share (%), by Country
  • Figure 8. Europe Virtual Clinical Trials Share (%), by Country
  • Figure 9. MEA Virtual Clinical Trials Share (%), by Country
  • Figure 10. North America Virtual Clinical Trials Share (%), by Country
  • Figure 11. Global Virtual Clinical Trials share by Players 2021 (%)
  • Figure 12. Global Virtual Clinical Trials share by Players (Top 3) 2021(%)
  • Figure 13. Global Virtual Clinical Trials share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. ICON, plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 16. ICON, plc (Ireland) Revenue: by Geography 2021
  • Figure 17. Parexel International Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 18. Parexel International Corporation (United States) Revenue: by Geography 2021
  • Figure 19. IQVIA (United States) Revenue, Net Income and Gross profit
  • Figure 20. IQVIA (United States) Revenue: by Geography 2021
  • Figure 21. Covance (United States) Revenue, Net Income and Gross profit
  • Figure 22. Covance (United States) Revenue: by Geography 2021
  • Figure 23. PRA Health Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 24. PRA Health Sciences (United States) Revenue: by Geography 2021
  • Figure 25. LEO Innovation Lab (Denmark) Revenue, Net Income and Gross profit
  • Figure 26. LEO Innovation Lab (Denmark) Revenue: by Geography 2021
  • Figure 27. Medidata Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 28. Medidata Solutions (United States) Revenue: by Geography 2021
  • Figure 29. Oracle (United States) Revenue, Net Income and Gross profit
  • Figure 30. Oracle (United States) Revenue: by Geography 2021
  • Figure 31. CRF Health (United States) Revenue, Net Income and Gross profit
  • Figure 32. CRF Health (United States) Revenue: by Geography 2021
  • Figure 33. Clinical Ink Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Clinical Ink Inc. (United States) Revenue: by Geography 2021
  • Figure 35. Medable, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Medable, Inc. (United States) Revenue: by Geography 2021
  • Figure 37. Global Virtual Clinical Trials: by Application USD Million (2022-2027)
  • Figure 38. Global Virtual Clinical Trials: by Design USD Million (2022-2027)
  • Figure 39. South America Virtual Clinical Trials Share (%), by Country
  • Figure 40. Asia Pacific Virtual Clinical Trials Share (%), by Country
  • Figure 41. Europe Virtual Clinical Trials Share (%), by Country
  • Figure 42. MEA Virtual Clinical Trials Share (%), by Country
  • Figure 43. North America Virtual Clinical Trials Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ICON, plc (Ireland)
  • Parexel International Corporation (United States)
  • IQVIA (United States)
  • Covance (United States)
  • PRA Health Sciences (United States)
  • LEO Innovation Lab (Denmark)
  • Medidata Solutions (United States)
  • Oracle (United States)
  • CRF Health (United States)
  • Clinical Ink Inc. (United States)
  • Medable, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2022 213 Pages 65 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as ICON, plc (Ireland), Parexel International Corporation (United States), IQVIA (United States), Covance (United States), PRA Health Sciences (United States), LEO Innovation Lab (Denmark), Medidata Solutions (United States), Oracle (United States), CRF Health (United States), Clinical Ink Inc. (United States) and Medable, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Virtual Clinical Trials Report?